LGC Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:LGC Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10819
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
LGC Ltd (LGC), formerly LGC (Teddington) Ltd is a life sciences measurement and testing company that offers reference materials, genomics solutions and analytical testing products and services. The company’s products comprise DNA extraction instrumentation, DNA extraction kits, Douglas scientific, genotyping chemistry, genotyping instruments, genotyping libraries and others. It offers services such as genotyping, consultancy, consumer product testing, digital forensic investigation, DNA and RNA extraction services, DNA sequencing, drug and alcohol testing, drug development services, food and agricultural analytical services and others. The company caters to agrigenomics, forensic science, food, government and academia; human genomics, pharma and healthcare and sports sectors. It serves its clients in the UK and abroad. LGC is headquartered in Teddington, the UK.

LGC Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
LGC Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
LGC Ltd, Medical Devices Deals, 2012 to YTD 2018 9
LGC Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
LGC Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
LGC Genomics To Acquire Bioanalytical Sciences Business Of Quotient BioResearch 11
Venture Financing 12
Lucigen Raises USD2.2 Million in Venture Financing 12
Lucigen Raises USD1.95 Million in Venture Financing 13
Lucigen Raises US$1.7 Million In Venture Financing 14
Private Equity 15
KKR to Acquire LGC from Bridgepoint 15
Partnerships 16
Lucigen Enters into Distribution Agreement with Illumina 16
Lucigen Enters into Distribution Agreement with Sigma-Aldrich 17
EnviroLogix Enters Into Distribution Agreement With Douglas Scientific 18
Lucigen Enters Into Distribution Agreement With Research Corporation Technologies For Endotoxin Free CleanColi Expression System 19
Link Technologies Enters Into Distribution Agreement With GeneDesign 20
ChromaDex Enters Into Distribution Agreement With LGC Standards For LoGiCal Reference Standards 21
EnviroLogix Enters Into Co-Development Agreement With Douglas Scientific 22
Life Technologies Enters Into Co-Marketing Agreement With Douglas Scientific 23
Licensing Agreements 24
LGC Enters into Licensing Agreement with Keygene 24
Biosearch Technologies Enters Into Licensing Agreement With Rutgers University For turboFISH Technology 25
Biosearch Technologies Enters Into Licensing Agreement With University of Medicine and Dentistry of New Jersey For Nucleic Acid Probe Technology 26
Acquisition 27
LGC Acquires Axolabs 27
LGC to Acquire Biosearch Technologies 28
Biosearch Technologies Acquires Majority Stake In LightSpeed Genomics 29
LGC Ltd – Key Competitors 30
LGC Ltd – Key Employees 31
LGC Ltd – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Joint Venture 33
Recent Developments 34
Corporate Communications 34
Sep 22, 2017: Dr. Juergen Mueller joins LGC as Commercial and Strategic Development Director, Oligo-therapeutics 34
Legal and Regulatory 35
Jul 03, 2018: NML awarded ISO17025 accreditation for digital PCR-based quantification of DNA 35
Product News 36
Jul 05, 2017: Meridian2 delivers high throughput liquid handling for PCR 36
Jan 16, 2017: Hydrocycler2 delivers high throughput thermal cycling for PCR 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
LGC Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
LGC Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
LGC Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
LGC Ltd, Medical Devices Deals, 2012 to YTD 2018 9
LGC Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
LGC Genomics To Acquire Bioanalytical Sciences Business Of Quotient BioResearch 11
Lucigen Raises USD2.2 Million in Venture Financing 12
Lucigen Raises USD1.95 Million in Venture Financing 13
Lucigen Raises US$1.7 Million In Venture Financing 14
KKR to Acquire LGC from Bridgepoint 15
Lucigen Enters into Distribution Agreement with Illumina 16
Lucigen Enters into Distribution Agreement with Sigma-Aldrich 17
EnviroLogix Enters Into Distribution Agreement With Douglas Scientific 18
Lucigen Enters Into Distribution Agreement With Research Corporation Technologies For Endotoxin Free CleanColi Expression System 19
Link Technologies Enters Into Distribution Agreement With GeneDesign 20
ChromaDex Enters Into Distribution Agreement With LGC Standards For LoGiCal Reference Standards 21
EnviroLogix Enters Into Co-Development Agreement With Douglas Scientific 22
Life Technologies Enters Into Co-Marketing Agreement With Douglas Scientific 23
LGC Enters into Licensing Agreement with Keygene 24
Biosearch Technologies Enters Into Licensing Agreement With Rutgers University For turboFISH Technology 25
Biosearch Technologies Enters Into Licensing Agreement With University of Medicine and Dentistry of New Jersey For Nucleic Acid Probe Technology 26
LGC Acquires Axolabs 27
LGC to Acquire Biosearch Technologies 28
Biosearch Technologies Acquires Majority Stake In LightSpeed Genomics 29
LGC Ltd, Key Competitors 30
LGC Ltd, Key Employees 31
LGC Ltd, Other Locations 32
LGC Ltd, Subsidiaries 32
LGC Ltd, Joint Venture 33

List of Figures
LGC Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
LGC Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
LGC Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[LGC Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Proengin SA:企業の戦略・SWOT・財務分析
    Proengin SA - Strategy, SWOT and Corporate Finance Report Summary Proengin SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Securitas AB (SECU B):企業の財務・戦略的SWOT分析
    Securitas AB (SECU B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Henry Schein, Inc.:企業の戦略・SWOT・財務情報
    Henry Schein, Inc. - Strategy, SWOT and Corporate Finance Report Summary Henry Schein, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Kenya Power and Lighting Co Ltd (KPLA):企業の財務・戦略的SWOT分析
    Kenya Power and Lighting Co Ltd (KPLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • MAX Resource Corp. (MXR):企業の財務・戦略的SWOT分析
    MAX Resource Corp. (MXR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Panera Bread Company:企業の戦略的SWOT分析
    Panera Bread Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Bonheur ASA (BON):企業の財務・戦略的SWOT分析
    Summary Bonheur ASA (Bonheur) is an oil and gas investment service provider that offers investment services for various energy sectors. The company invests in renewable energy, cruise, shipping and offshore wind, offshore drilling, and other investments. It operates shipping vessels for transport an …
  • Bank of Cyprus Public Company Ltd:企業のM&A・事業提携・投資動向
    Bank of Cyprus Public Company Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of Cyprus Public Company Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • GUD Holdings Limited (GUD):企業の財務・戦略的SWOT分析
    GUD Holdings Limited (GUD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • MyCartis NV:医療機器:M&Aディール及び事業提携情報
    Summary MyCartis NV (MyCartis), formerly Pronota NV, is an immuno-diagnostic solution provider. The company offers Evalution, a multiplex analysis platform that designs and develops protein and nucleic acid based biomarkers; and provides opportunity for researchers and assay developers to build mult …
  • Downer EDI Ltd (DOW):企業の財務・戦略的SWOT分析
    Downer EDI Ltd (DOW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • The Capital Group Companies, Inc.:企業の戦略・SWOT・財務分析
    The Capital Group Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Capital Group Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • WABCO Holdings Inc.:企業の戦略・SWOT・財務情報
    WABCO Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary WABCO Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Salk Institute for Biological Studies:製薬・医療:M&Aディール及び事業提携情報
    Summary Salk Institute for Biological Studies (Salk) is a research institute that offers biological research programs. The institute’s areas of research comprise aging and regenerative medicine, cancer biology, immune system biology, metabolism and diabetes, neuroscience and neurological disorders, …
  • Lansen Pharmaceutical Holdings Ltd (503):企業の財務・戦略的SWOT分析
    Summary Lansen Pharmaceutical Holdings Ltd (Lansen), a subsidiary of Cathay International Holdings Ltd is a pharmaceutical that develops, produces and sales specialty prescription western pharmaceuticals for the treatment of rheumatic diseases. The company’s products comprise specialist medicine, Ch …
  • Perry Ellis International Inc:企業のM&A・事業提携・投資動向
    Perry Ellis International Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Perry Ellis International Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Kumagai Gumi Co Ltd (1861):企業の財務・戦略的SWOT分析
    Kumagai Gumi Co Ltd (1861) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • MetLife, Inc.:企業の戦略・SWOT・財務情報
    MetLife, Inc. - Strategy, SWOT and Corporate Finance Report Summary MetLife, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Cineplex Inc:企業の戦略・SWOT・財務情報
    Cineplex Inc - Strategy, SWOT and Corporate Finance Report Summary Cineplex Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • iKang Healthcare Group Inc:企業の戦略・SWOT・財務情報
    iKang Healthcare Group Inc - Strategy, SWOT and Corporate Finance Report Summary iKang Healthcare Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆